Abstract
Proteases of the malaria parasite Plasmodium falciparum have long been investigated as drug targets. The P. falciparum genome encodes 10 aspartic proteases called plasmepsins, which are involved in diverse cellular processes. Most have been studied extensively but the functions of plasmepsins IX and X (PMIX and PMX) were unknown. Here we show that PMIX is essential for erythrocyte invasion, acting on rhoptry secretory organelle biogenesis. In contrast, PMX is essential for both egress and invasion, controlling maturation of the subtilisin-like serine protease SUB1 in exoneme secretory vesicles. We have identified compounds with potent antimalarial activity targeting PMX, including a compound known to have oral efficacy in a mouse model of malaria.
Considerable work has gone into the synthesis of plasmepsin inhibitors as antimalarials (1–4). Most efforts have been directed at the digestive vacuole plasmepsins I to IV (PMI to PMIV) because of the availability of crystal structures and recombinant proteins. However, genetic knockouts reveal that these are not essential for parasite survival (5). Thus, rationally designed inhibitors of PMI to PMIV likely exert their antimalarial effects through other targets (1, 3). PMV, PMIX, and PMX are the only other plasmepsins expressed in asexual blood-stage parasites (6). PMV is an essential protease that processes proteins for export into the host erythrocyte and is a focus of ongoing drug development efforts (7–9). PMV is, however, quite divergent from the other plasmepsins (10), and most digestive vacuole plasmepsin inhibitors are not potent against this enzyme (11). PMI to PMIV share more sequence homology to PMIX and PMX (10). PMIX and PMX could be the targets of digestive vacuole plasmepsin inhibitors that have antimalarial activity.
To characterize the functions of PMIX and PMX in the biology of blood-stage Plasmodium falciparum parasites, we used new TetR-aptamer conditional knockdown (KD) technology (12) (fig. S1), enabling translational repression of the target gene when anhydrotetracycline (aTc) is removed from the culture. Using CRISPR-Cas9 editing, we installed the TetR-aptamer regulatory system at the PMIX and PMX loci to create PMIXapt and PMXapt lines (fig. S1). When aTc levels were lowered in synchronous, early ringstage parasites, we observed a major decrease in target protein levels in late-stage schizonts, in both PMIXapt and PMXapt (Fig. 1A). This led to decreased replication, revealing a critical role for both of these enzymes in parasite survival (Fig. 1B).
To determine the stage at which the defect occurred, cell cycle progression was monitored using highly synchronous ring-stage parasites cultured under KD (–aTc) or induced (+aTc) conditions. Flow cytometry revealed that both PMIXapt and PMXapt developed normally until they reached segmented schizonts (~44 hours). At the end of the cycle (between 46 to 52 hours), similar numbers of PMIXapt schizonts had egressed, irrespective of PMIX expression status. However, –aTc cultures featured about one-fourth as many new rings (Fig. 1C). A similar fourfold decrease was seen in –aTc PMXapt cultures (Fig. 1D). Unlike for PMIXapt, at 52 hours, 80% of PMXapt parasites had egressed in +aTc cultures, whereas only 36% had egressed in –aTc cultures. Even taking the egress defect into account, however, we observed fewer rings than expected, indicating an additional invasion phenotype. We further characterized this by live microscopy of individual cells (13) (Fig. 1E) and observed similar egress and invasion impairment (Fig. 1F). Unruptured schizonts accumulated in the –aTc culture as merozoite clusters and some distorted schizonts; occasionally, these partially ruptured or displayed defective merozoite dispersal (Fig. 1G). Of the parasites that could egress in a normal time frame under –aTc conditions, the merozoite invasion rate was ~50% of that observed in the presence of aTc (Fig. 1F). These data implicate PMIX in erythrocyte invasion and PMX in both egress and invasion. A PMIXapt-PMXapt double aptamer– tagged line displayed a similar defect in egress and a greater block in invasion, yielding a sevenfold decrease in new rings (fig. S2). The data imply independent contributions of PMIX and PMX to these processes.
To evaluate the subcellular localization of these proteins, we engineered epitope tags on the 3′ end of the endogenous genes (fig. S3) and performed immuno–electron microscopy. PMIX was found largely in the bulbs of rhoptry secretory organelles that are involved in invasion (14) (Fig. 2, A and B). PMX was found in exonemes—small, ovoid secretory vesicles that discharge during egress into the parasitophorous vacuole surrounding the parasite (15) (Fig. 2, C to E).
The localization studies guided us to examine organellar proteins whose processing could be affected by PM action. RAP1 is a rhoptry bulb protein that is processed from an 84-kDa precursor to 82- and 67-kDa forms. The PMIXapt line failed to process the precursor efficiently when aTc was withdrawn (Fig. 3A). In contrast, the rhoptry neck protein RON4 was processed despite PMIX KD. By electron microscopy, a rhoptry biogenesis defect was evident under KD conditions (Fig. 2, F and G).
The subtilisin-like serine protease SUB1 is an exonemal protein that plays a critical role in egress and invasion (15, 16). SUB1 is synthesized as an 82-kDa zymogen that rapidly self-processes into a 54-kDa semi-proenzyme in the endoplasmic reticulum (ER). The cleaved prodomain remains bound to the 54-kDa protein and inhibits activity (17). A second processing step converts the 54-kDa form into a 47-kDa mature protein. This step can occur autocatalytically in vitro but is slow and partial (18, 19). A processing enzyme has been postulated for this step (20), but its identity is unclear. Notably, a major defect in SUB1 processing was observed in PMXapt (Fig. 3B) but not PMIXapt (fig. S4) after aTc withdrawal, indicating that PMX is important for the final SUB1 processing step. Consistent with this, PMX is synthesized and processed shortly before SUB1 synthesis and processing occurs (Fig. 3C). Similar to the second processing step of SUB1, PMX maturation is blocked by brefeldin A (fig. S5), suggesting a post-ER event.
During egress, SUB1 processes a family of cysteine proteases (SERAs) and a family ofmerozoite surface proteins (MSPs) (15, 16). SERA5 is synthesized as a 126-kDa protein and is processed sequentially by SUB1 into 73- and 56-kDa forms. The latter is further processed into a 50-kDa fragment in a SUB1-independent process (21). We assessed SERA5 in PMXapt parasites. In the absence of aTc, SERA5 accumulated in the 126-kDa form with very little processing to other intermediates (Fig. 3D). Similarly, MSP1 accumulated as its 193-kDa precursor (fig. S6). Thus, PMX KD impairs downstream egress events.
We tested whether PMX is an active protease by introducing an ectopic gene copy (Fig. 3, E and F, and fig. S7). PMXapt parasites constitutively expressing a second-copy PMX gene with an active site aspartate mutation [Asp266→Gly266 (D266G)] had reduced growth in the absence of aTc and were unable to restore processing of SUB1. In contrast, those expressing a wild-type second-copy gene were rescued. These data show that PMX enzymatic activity in vivo is crucial to its function. The catalytic mutant PMX was processed to the mature form, suggesting a transprocessing event (fig. S7B).
Many aspartic protease inhibitors with antimalarial properties have been investigated, but the specific targets for most of them are unknown (1). Three aminohydantoins that caused schizont accumulation reminiscent of our PMX KD phenotype were identified [TCMD-134675 and TCMD- 136879 from the TCAMS collection (22) and CWHM-117 (11)]. To evaluate whether these compounds act in a PMIX- or PMX-dependent manner, dose-response curves were determined for KD parasites. The half-maximal effective concentration values were substantially lower for PMXapt but not PMIXapt cultured in low-aTc conditions (Fig. 4, A and B). This indicates hypersensitivity of PMXapt parasites to aminohydantoins when PMX expression is low. Egress and invasion were blocked, and an accumulation of abnormal schizonts was observed by live-cell microscopy as shown with CWHM-117 (Fig. 4, C and D). Further, treatment of parasites with each of these inhibitors blocked SUB1 and SERA5 maturation (Fig. 4E), as was seen with PMX KD. Treatment with aminohydantoins did not block the initial SUB1 autoprocessing step. The compounds also did not inhibit PMX maturation (Fig. 4E). Recombinant PMX cleaved a fluorogenic peptide as well as SUB1 protein in vitro, and these reactions were blocked by aminohydantoins (Fig. 4F and fig. S9), with median inhibitory concentration values from 175 to 800 nM in the peptide assay. Combining PMX KD and inhibitor treatment resulted in a complete block of egress and SUB1 maturation (Fig. 4, G and H). Because CWHM-117 has oral efficacy in a mouse model (11), it appears that PMX is a promising target for antimalarial chemotherapy.
We have determined that PMIX and PMX are essential for parasite egress and invasion. PMIX localizes to the rhoptries and could be a maturase for proteins in this organelle.We have discovered thatPMXis required for SUB1 processing,making PMX the most upstream protease known in the egress cascade (Fig. 4I). However, it is not clear that the final cleavage of SUB1 is a direct action of PMX; if so, it could result from processing of semi-pro SUB1 or fromcleavage of the prodomain, liberating semi-pro SUB1 to process itself. PMX is capable of cleaving SUB1 in vitro (fig. S9), adding some support to the direct-cleavage model.
PMX does not appear to autoprocess (Fig. 4E and fig. S7B), unlike most aspartic proteases, which suggests that there may be another stillundiscoveredmaturase upstream in the proteolytic cascade of egress. We have identified compounds with a common scaffold that are specific inhibitors of PMX and that recapitulate the actions of PMX KD phenotypically. Our PMIX and PMX lines should allow high-throughput screening of aspartic protease inhibitor collections andmay inform efforts to improve on the promising CWHM-117 lead compound.
Supplementary Material
ACKNOWLEDGMENTS
All data needed to understand and assess the conclusions of this research are available in the main paper and supplementary materials. We thank W. Beatty for immuno–electron microscopy, A. Odom John for the HAD1 antibody, K. Brown for compound 1, M. Blackman for SERA5 and SUB1 antibodies, E. Istvan for helpful suggestions, and D. Sibley for critical review of the manuscript. This work was supported by NIH grant AI-112508. J.R.B. was supported by NIH K99 grant HL133453. J.C.N. was supported by NIH P50 grant GM098792 and a grant from the Bill and Melinda Gates Foundation (OPP1069759). This work was supported in part by the Division of Intramural Research of the NICHD. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.
SUPPLEMENTARY MATERIALS
www.sciencemag.org/content/358/6362/518/suppl/DC1
Materials and Methods
Figs. S1 to S9
References (23–29)
REFERENCES AND NOTES
- 1.Meyers M. J., Goldberg D. E., Curr. Top. Med. Chem. 12, 445–455 (2012). [DOI] [PubMed] [Google Scholar]
- 2.Boss C., et al. , Curr. Med. Chem. 10, 883–907 (2003). [DOI] [PubMed] [Google Scholar]
- 3.Rasina D., et al. , J. Med. Chem. 59, 374–387 (2016). [DOI] [PubMed] [Google Scholar]
- 4.Bhaumik P., Gustchina A., Wlodawer A., Biochim. Biophys. Acta 1824, 207–223 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Bonilla J. A., Bonilla T. D., Yowell C. A., Fujioka H., Dame J. B., Mol. Microbiol. 65, 64–75 (2007). [DOI] [PubMed] [Google Scholar]
- 6.Banerjee R., et al. , Proc. Natl. Acad. Sci. U.S.A. 99, 990–995 (2002). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Russo I., et al. , Nature 463, 632–636 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Boddey J. A., et al. , Nature 463, 627–631 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Hodder A. N., et al. , Nat. Struct. Mol. Biol. 22, 590–596 (2015). [DOI] [PubMed] [Google Scholar]
- 10.Coombs G. H., et al. , Trends Parasitol. 17, 532–537 (2001). [DOI] [PubMed] [Google Scholar]
- 11.Meyers M. J., et al. , ACS Med. Chem. Lett. 5, 89–93 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Ganesan S. M., Falla A., Goldfless S. J., Nasamu A. S., Niles J. C., Nat. Commun. 7, 10727 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Glushakova S., Yin D., Gartner N., Zimmerberg J., Malar. J. 6, 61 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Sharma P., Chitnis C. E., Curr. Opin. Microbiol. 16, 432–437 (2013). [DOI] [PubMed] [Google Scholar]
- 15.Yeoh S., et al. , Cell 131, 1072–1083 (2007). [DOI] [PubMed] [Google Scholar]
- 16.Koussis K., et al. , EMBO J. 28, 725–735 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Giganti D., et al. , Nat. Commun. 5, 4833 (2014). [DOI] [PubMed] [Google Scholar]
- 18.Sajid M., Withers-Martinez C., Blackman M. J., J. Biol. Chem. 275, 631–641 (2000). [DOI] [PubMed] [Google Scholar]
- 19.Withers-Martinez C., et al. , J. Biol. Chem. 277, 29698–29709 (2002). [DOI] [PubMed] [Google Scholar]
- 20.Arastu-Kapur S., et al. , Nat. Chem. Biol. 4, 203–213 (2008). [DOI] [PubMed] [Google Scholar]
- 21.Stallmach R., et al. , Mol. Microbiol. 96, 368–387 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Gamo F. J., et al. , Nature 465, 305–310 (2010). [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.